Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RNAZ | US
-0.08
-11.79%
Healthcare
Biotechnology
30/06/2024
17/10/2024
0.60
0.69
0.69
0.57
TransCode Therapeutics Inc. a ribonucleic acid (RNA) oncology company focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b a master regulator of metastatic cell viability in a range of cancers including breast pancreatic ovarian colon cancer glioblastomas and others. The company is also developing TTX-siPDL1 an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition the company developing TTX-RIGA an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics Inc. was incorporated in 2016 and is based in Boston Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
240.9%1 month
293.0%3 months
224.5%6 months
228.4%0.00
-
9.14
0.17
0.05
-0.59
-
-
-17.68M
10.78M
10.78M
-
-
-
-
-1.05K
0.45
8.01
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.40
Range1M
0.53
Range3M
0.73
Rel. volume
0.31
Price X volume
577.86K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
DOMH | DOMH | Biotechnology | 1.88 | 11.80M | -3.09% | n/a | 7.66% |
BioRestorative Therapies Inc | BRTX | Biotechnology | 1.6815 | 11.64M | -2.80% | n/a | 0.77% |
Jaguar Health Inc | JAGX | Biotechnology | 1.23 | 11.37M | 0.00% | 0.26 | 176.14% |
Common Stock | ADXN | Biotechnology | 10.6 | 11.33M | 0.47% | n/a | 0.25% |
Immuron Limited | IMRN | Biotechnology | 1.97 | 11.22M | -1.99% | n/a | 1.37% |
Evogene Ltd | EVGN | Biotechnology | 2.14 | 11.15M | -16.08% | n/a | 26.41% |
Sensei Biotherapeutics Inc | SNSE | Biotechnology | 0.4237 | 10.66M | -7.69% | n/a | 9.67% |
RedHill Biopharma Ltd | RDHL | Biotechnology | 8.205 | 10.51M | -3.36% | n/a | 65.80% |
Alterity Therapeutics Limited | ATHE | Biotechnology | 1.2 | 10.49M | -4.00% | n/a | 1.15% |
GlycoMimetics Inc | GLYC | Biotechnology | 0.1585 | 10.22M | 1.02% | n/a | 2.24% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.59 | 0.53 | Cheaper |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | 0.00 | 40.42 | Cheaper |
Price to Book | 9.14 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 224.49 | 72.92 | Riskier |
Debt to Equity | 0.17 | -1.24 | Expensive |
Debt to Assets | 0.05 | 0.25 | Cheaper |
Market Cap | 10.78M | 3.78B | Emerging |